Drugs, Key Data 2010
OFDT, 6 p.
In France, the Interministerial mission for the fight against drugs and drug addiction (MILDT - Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie) is responsible for co-ordinating government action in the domain of prevention, health and social care, law enforcement, training, communication, research and international exchanges; the MILDT reports to the Prime Minister.
The MILDT's field of action today covers all illegal drugs in addition to alcohol and tobacco abuse and addiction.
In order to have access to confirmed scientific data and the clearest possible overview of consumption levels, treatments, health-related or social consequences and trafficking, the MILDT draws heavily upon the work carried out and the data gathered by a public interest group, the French monitoring centre for drugs and drugs addiction (OFDT - Observatoire français des drogues et des toxicomanies). This document, produced by the OFDT, provides the most recent and relevant figures in order to measure drug-related phenomena.
This third edition represents the update of the initial June 2009 document.The first part gives the framework data and definitions concerning the number of users for each of the various substances. Key data is then presented for each substance in turn.
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.